



ALKEM LABORATORIES LTD.

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

Date: 25.05.2021

To,
National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051.
Fax No.: 022-26598237/38/26598347

BSE Ltd.,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.
Tel: 022-22721233/4
Fax No 022-22723121

Dear Sir/ Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is to inform you that the Company at its meeting held today i.e. 25th May, 2021, has approved the restructuring of the Company's Subsidiaries in USA.

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Para A of Part A of Schedule III of the aforesaid Regulations, is attached as per "Annexure A".

A copy of the said disclosure will be made available on the Company's website as well in accordance with Regulation 30(8) of the aforesaid Regulations.

This is for your information and record.

Thanking you,

Yours faithfully,

For Alkem Laboratories Limited

Manish Narang
President – Legal, Company Secretary & Compliance Officer

Encl:

Annexure A



ALKEM LABORATORIES LTD.

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

Annexure A

Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 under Para A of Part A, Schedule III of the aforesaid regulations for restructuring of the Company's subsidiaries in USA.

<p>a) Details and reasons for restructuring;</p>	<p>For the ease of administration and simplification in the organization structure, the restructuring of the Company's subsidiaries namely S & B Pharma Inc, USA ("S & B"), The PharmaNetwork LLC, USA ("TPNC") and S & B Holdings BV, Netherlands ("S & B BV") shall involve the following steps:</p> <ol style="list-style-type: none">Incorporation of a wholly owned single member LLC named S&B Pharma, LLC ("New LLC") in USA owned by the TPNC;Acquisition of S & B from the Company by TPNC against consideration in the form of TPNC's membership interest, resulting in change in ownership of S & B from the Company to TPNC;Dissolution of S & B as per the laws of USA and consequently, transfer of S & B's asset and liabilities to TPNC;Transfer of such acquired assets and liabilities by TPNC to the New LLC against equity;Elimination of S&B Holdings BV. <p>The above is subject to necessary statutory and regulatory approvals including the approval of National Company Law Tribunal.</p>
--	---

**ALKEM LABORATORIES LTD.**

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

b) Quantitative and/ or qualitative effect of restructuring;	a. Consolidation of the Company's subsidiaries in the USA shall lead to operational, management and business synergies and reduce the duplication of costs like administration, sales, marketing, etc.; b. Consolidation of the Company's entire business operations in the USA; c. Elimination of S&B Holdings BV shall lead to reduced administrative cost;
c) Details of benefit, if any, to the promoter/promoter group/group companies from such proposed restructuring;	There will be no additional benefit to promoter/promoter group/group companies as a result of the proposed restructuring.
d) Brief details of change in shareholding pattern (if any) of all entities.	There will be no change in the shareholding pattern of the Company as a result of the proposed restructuring.